ACADIA Non Current Liabilities Total from 2010 to 2025
| ACAD Stock | USD 17.07 0.12 0.70% |
Non Current Liabilities Total | First Reported 2003-12-31 | Previous Quarter 55.7 M | Current Value 60.1 M | Quarterly Volatility 25.1 M |
Check ACADIA Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ACADIA Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 8 M, Selling General Administrative of 512.8 M or Total Revenue of 1 B, as well as many indicators such as Price To Sales Ratio of 3.02, Dividend Yield of 0.0 or PTB Ratio of 4.46. ACADIA financial statements analysis is a perfect complement when working with ACADIA Pharmaceuticals Valuation or Volatility modules.
ACADIA | Non Current Liabilities Total |
Latest ACADIA Pharmaceuticals' Non Current Liabilities Total Growth Pattern
Below is the plot of the Non Current Liabilities Total of ACADIA Pharmaceuticals over the last few years. It is ACADIA Pharmaceuticals' Non Current Liabilities Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ACADIA Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Non Current Liabilities Total | 10 Years Trend |
|
Non Current Liabilities Total |
| Timeline |
ACADIA Non Current Liabilities Total Regression Statistics
| Arithmetic Mean | 24,890,228 | |
| Geometric Mean | 3,715,585 | |
| Coefficient Of Variation | 115.28 | |
| Mean Deviation | 26,420,660 | |
| Median | 9,222,000 | |
| Standard Deviation | 28,694,683 | |
| Sample Variance | 823.4T | |
| Range | 63.2M | |
| R-Value | 0.82 | |
| Mean Square Error | 282.9T | |
| R-Squared | 0.68 | |
| Significance | 0.000086 | |
| Slope | 4,967,666 | |
| Total Sum of Squares | 12350.8T |
ACADIA Non Current Liabilities Total History
About ACADIA Pharmaceuticals Financial Statements
ACADIA Pharmaceuticals stakeholders use historical fundamental indicators, such as ACADIA Pharmaceuticals' Non Current Liabilities Total, to determine how well the company is positioned to perform in the future. Although ACADIA Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in ACADIA Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on ACADIA Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in ACADIA Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Non Current Liabilities Total | 60.1 M | 63.1 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out the analysis of ACADIA Pharmaceuticals Correlation against competitors. For information on how to trade ACADIA Stock refer to our How to Trade ACADIA Stock guide.You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ACADIA Pharmaceuticals. If investors know ACADIA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ACADIA Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 2.133 | Earnings Share 1.36 | Revenue Per Share | Quarterly Revenue Growth 0.124 | Return On Assets |
The market value of ACADIA Pharmaceuticals is measured differently than its book value, which is the value of ACADIA that is recorded on the company's balance sheet. Investors also form their own opinion of ACADIA Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is ACADIA Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ACADIA Pharmaceuticals' market value can be influenced by many factors that don't directly affect ACADIA Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ACADIA Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if ACADIA Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ACADIA Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.